Ovarian Neoplasms: all 2,757 studies
Page 6 of 28. Open to participants first (735), then studies with results posted, then the rest; newest registration first within each.
- A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid TumorsRecruitingNCT05932862Phase 1
- The Effectiveness of Liquid Biopsy in Differential Diagnosis and Early Screening of Epithelial Ovarian CancerNot yet recruitingNCT05931055
- The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of ActionRecruitingNCT05926336Phase 4
- Plasmodium Immunotherapy for Advanced Ovarian CancerNot yet recruitingNCT05924776Phase 2/3
- Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian CancerNot yet recruitingNCT05921149Not applicable
- Immunotherapy-related CRP Kinetics in Metastatic Gynecological MalignanciesRecruitingNCT05914974
- An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and OlaparibRecruitingNCT05887609Phase 2
- A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationRecruitingNCT05877599Phase 1
- Development of a Biomarker to Predict the Efficacy of Anti-angiogenic Therapy in Ovarian CancerRecruitingNCT05874115
- ULTRA-LAP Trial: Laparoscopic Debulking Surgery (LDS) in Advanced Ovarian CancerRecruitingNCT05862740Not applicable
- Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer RecurrenceRecruitingNCT05856409
- Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)RecruitingNCT05855941
- PPK Study Based on Quantitative Pharmacology in Patients With PamiprilRecruitingNCT05848648
- Improved Diagnosis of Ovarian CancerRecruitingNCT05842629
- Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)RecruitingNCT05827523Phase 3
- A Prospective Cohort Study of 68ga-FAPI-pet-ct Versus FDG-pet-ct for Ovarian CancerRecruitingNCT05824247
- FRAGINOC Study: Screening and Geriatric Assessment and Intervention in Older Patients With Epithelial Ovarian CancerRecruitingNCT05810701Not applicable
- Hyperpolarized 13C MRI for Cancer ImmunotherapyNot yet recruitingNCT05805358Phase 2
- Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)RecruitingNCT05804370Phase 3
- A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological MalignanciesRecruitingNCT05803018Phase 1/2
- Appraising Medical Trial Experiences of Ovarian Cancer PatientsNot yet recruitingNCT05801796
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian CancerRecruitingNCT05801783Early Phase 1
- ctDNA Methylation for Detecting Ovarian CancerRecruitingNCT05801276
- ctDNA Methylation for Epithelial Ovarian CancerRecruitingNCT05801263
- Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsRecruitingNCT05797168Phase 1/2
- Measuring Oncological Value of Exercise and StatinRecruitingNCT05796973Phase 3
- Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian CancerNot yet recruitingNCT05794659Phase 2
- DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating MutationsRecruitingNCT05786716Phase 2/3
- NEOadjuvant Dendritic Cell Vaccination for Ovarian CancerRecruitingNCT05773859Phase 1/2
- Prediction of Germline BRCA 1/2 Genes From Healthy OvariesRecruitingNCT05769517
- MRI in Ovarian TumorsNot yet recruitingNCT05769205Not applicable
- DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.RecruitingNCT05768178Phase 2/3
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingNCT05768139Phase 1/2
- Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a BiomarkerRecruitingNCT05763511
- Trial of Exercise and Lifestyle for Women With Ovarian and Endometrial CancerRecruitingNCT05761561Not applicable
- First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid TumoursRecruitingNCT05759923Phase 1
- Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.RecruitingNCT05753826Phase 2
- Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)RecruitingNCT05752448Not applicable
- Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian CancerNot yet recruitingNCT05749211Not applicable
- A Study of Hansoh (HS)-10502 in Patients With Advanced Solid TumorsRecruitingNCT05740956Phase 1
- Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal CancerRecruitingNCT05739981Phase 1/2
- Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian CancerRecruitingNCT05737303Phase 3
- Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerRecruitingNCT05735080Phase 1/2
- CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid TumorsRecruitingNCT05733000Phase 2
- With Love, Grandma ("Con Cariño, Abuelita") Pilot StudyRecruitingNCT05721976Not applicable
- Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor MaintenanceRecruitingNCT05704621Phase 2
- Predictors of Ovarian Cancer and Endometrial Cancer for Artificial-Intelligence-Based Screening ToolsRecruitingNCT05697601
- Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian CancerRecruitingNCT05684731Phase 1
- Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube CancerRecruitingNCT05659381Phase 3
- Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian CancerRecruitingNCT05652283Phase 2
- Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.RecruitingNCT05649072Not applicable
- LIVInG With chrONic Cancer TrEatments (LONGEVITI) StudyRecruitingNCT05645510
- DKI Combined With APT for Post-treatment Assessment of Ovarian Malignancies and Correlation With XRCC2 GeneNot yet recruitingNCT05642871
- A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian CancerNot yet recruitingNCT05641506Phase 2
- Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian CancerRecruitingNCT05636111Phase 1
- Combination Therapy for Recurrent Ovarian CancerRecruitingNCT05610735Phase 1/2
- Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses.RecruitingNCT05610501
- Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 TrialRecruitingNCT05607329Not applicable
- Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)RecruitingNCT05606692Phase 4
- Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian CancerNot yet recruitingNCT05597527Phase 2
- A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyRecruitingNCT05585281Phase 2
- Efficacy and Adverse Effects of Niraparib in Ovarian Cancer.Not yet recruitingNCT05583799
- Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)RecruitingNCT05579366Phase 1/2
- Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination PhenotypeRecruitingNCT05574673
- SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or MesotheliomaRecruitingNCT05568680Phase 1
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 2
- Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPiRecruitingNCT05551208Phase 2
- A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF AlterationsRecruitingNCT05503797Phase 2
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)RecruitingNCT05489211Phase 2
- Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance TreatmentNot yet recruitingNCT05479487Phase 2
- A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line TherapyRecruitingNCT05460000Phase 2
- Clinical Study on the Re-irradiation of Lateral Pelvic Recurrences of Gynecological MalignanciesRecruitingNCT05457595Not applicable
- Intraperitoneal Lidocaine in Ovarian Cancer SurgeryNot yet recruitingNCT05450055Not applicable
- Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian CancerRecruitingNCT05446545
- Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian CancerRecruitingNCT05444270Not applicable
- Assessment of Quality of Life After Low Anterior Resection During Cytoreductive Surgery for Advanced Ovarian CancerRecruitingNCT05431530
- AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian CancerRecruitingNCT05430906Phase 2
- A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)RecruitingNCT05429970Not applicable
- Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid TumoursRecruitingNCT05427487Phase 1
- Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesRecruitingNCT05417594Phase 1/2
- New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer RecurrenceRecruitingNCT05410028
- Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian CancerRecruitingNCT05410015
- Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)RecruitingNCT05403177
- Chemotherapy Supported by Autologous Hematopoietic Stem CellsRecruitingNCT05401162Not applicable
- A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid TumorsRecruitingNCT05377996Phase 1/2
- cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseRecruitingNCT05366881
- Prehabilitation for Ovarian Cancer PatientsRecruitingNCT05364879Not applicable
- Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian CancerRecruitingNCT05316129Phase 1
- HRD and Resistance to PAPPi in EOC PatientsRecruitingNCT05310370
- Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With CancerRecruitingNCT05297734Not applicable
- Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic CancersRecruitingNCT05296564Phase 1/2
- Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort StudyRecruitingNCT05287451Not applicable
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)RecruitingNCT05281471Phase 3
- Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian CancerRecruitingNCT05272462Phase 2
- MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.RecruitingNCT05255471Phase 3
- A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omicsRecruitingNCT05251883
- Retrospective Study of BrachytherapyRecruitingNCT05242861
- Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian CancerRecruitingNCT05236686Not applicable
- MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal CancerRecruitingNCT05233982Phase 2
- Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian CancerRecruitingNCT05231122Phase 2